Buchfuhrer, Mark J.
Roy, Asim
Rodriguez, Stephanye
Charlesworth, Jonathan D.
Funding for this research was provided by:
National Institute of Neurological Disorders and Stroke (R44NS117294, R44NS117294, R44NS117294, R44NS117294)
Article History
Received: 2 August 2023
Accepted: 10 November 2023
First Online: 21 November 2023
Declarations
:
: The study was conducted in accordance with the International Conference on Harmonization guidelines on good clinical practice and the Declaration of Helsinki. The study protocol and informed consent were approved by a central institutional review board (WCG Institutional Review Board). All participants provided informed consent.
: Not applicable.
: MJB received research support from Noctrix Health, received consulting fees from Noctrix Health, received payment for lectures from Azurity Pharmaceuticals, received support for attending meetings from Noctrix Health, and owns stock options in Noctrix Health. AR received research support from Noctrix Health, received grants or contracts for clinical trials from Jazz Pharma, Inspire, and Harmony Bio, and received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Jazz Pharma, Inspire, and Harmony Bio. SR was not employed by Noctrix Health at any point during this study but is now a full-time employee for Noctrix Health. JDC is a full-time employee for Noctrix Health, Inc, with associated patents planned, issued, or pending, stock or stock options, and support for attending meetings and/or travel and is principal investigator on NIH/NINDS R44NS117294.